Volume 65, Issue 5, Pages (May 2004)

Slides:

Advertisements

Similar presentations

Evaluation and treatment of coronary artery disease in patients with end-stage renal disease Peter A. McCullough Kidney International Volume 67, Pages.

Advertisements

Reduced renal function in patients with simple renal cysts

Diagnosis and Management of Chronic Kidney Disease

Mitchell H. Rosner, W. Kline Bolton Kidney International

Volume 83, Issue 3, Pages (March 2013)

Membranous nephropathy: When and how to treat

Kidney transplantation in a low-resource setting: Nigeria experience

Volume 61, Issue 2, Pages (February 2002)

Management of Acute Kidney Injury: Core Curriculum 2018

Mycophenolate mofetil treatment for primary glomerular diseases

Continuous renal replacement therapy in the critically ill patient

Volume 80, Issue 10, Pages (November 2011)

Mortality caused by sepsis in patients with end-stage renal disease compared with the general population Mark J. Sarnak, Bertrand L. Jaber Kidney International

Burden of chronic kidney disease: North Africa

Francesco Paolo Schena Kidney International

Better nephrology for mice—and man

Volume 70, Pages S21-S25 (December 2006)

End-stage renal disease in living kidney donors

Comorbidity and confounding in end-stage renal disease

Acute myocardial infarction in patients with chronic kidney disease: how are the most vulnerable patients doing? Gautam R. Shroff, Charles A. Herzog

Volume 74, Issue 3, Pages (August 2008)

Volume 86, Issue 5, Pages (November 2014)

Volume 70, Issue 11, Pages (December 2006)

Fernando Valderrábano, Francisco Gómez-Campderá, Elizabeth H.P. Jones

Renal risk scores: Progress and prospects

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

Volume 63, Issue 1, Pages (January 2003)

Long-term study of mycophenolate mofetil treatment in IgA nephropathy

Volume 87, Issue 2, Pages (February 2015)

Pieter Evenepoel, Björn K. Meijers Kidney International

The analysis of survival data: the Kaplan–Meier method

Volume 71, Issue 6, Pages (March 2007)

Prospective randomized study of individual and group psychotherapy versus controls in recipients of renal transplants1 Lyndsay S. Baines, John T. Joseph,

Volume 70, Issue 12, Pages (December 2006)

Volume 67, Pages S48-S51 (January 2005)

Volume 76, Issue 5, Pages (September 2009)

Volume 68, Issue 2, Pages (August 2005)

Extracorporeal therapy in sepsis: are we there yet?

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Volume 87, Issue 1, Pages (January 2015)

Non-immunologic intervention in chronic allograft nephropathy

Elevated risk of stroke among patients with end-stage renal disease

Reduced renal function in patients with simple renal cysts

V.R. Sørensen, P.M. Hansen, J. Heaf, B. Feldt-Rasmussen

Lynda Anne Szczech, Ira L. Lazar Kidney International

Volume 74, Issue 5, Pages (September 2008)

A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease S. Susan Hedayati, Venkata Yalamanchili,

Volume 69, Issue 8, Pages (April 2006)

Keng-Thye Woo, Yeow-Kok Lau, Kok-Seng Wong, Gilbert Shih-Chen Chiang

Volume 81, Issue 9, Pages (May 2012)

Volume 74, Issue 5, Pages (September 2008)

Homocysteine, renal function, and risk of cardiovascular disease

Volume 82, Issue 7, Pages (October 2012)

Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients B. Bammens, P. Evenepoel, H. Keuleers,

Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors Barry M. Brenner, Joann Zagrobelny

Low triiodothyronine and survival in end-stage renal disease

Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms Bert Bammens, Pieter Evenepoel, Kristin.

The Iranian model of living renal transplantation

Volume 80, Issue 10, Pages (November 2011)

Charles A. Herzog Kidney International

Is complement a target for therapy in renal disease?

Renal replacement therapy in Latin America

Giuseppe Remuzzi, Carlos Chiurchiu, Piero Ruggenenti

Volume 75, Issue 7, Pages (April 2009)

Volume 70, Issue 10, Pages (November 2006)

Hemodialysis access failure: a call to action—revisited

Volume 80, Issue 9, Pages (November 2011)

Volume 58, Issue 5, Pages (November 2000)

Volume 77, Issue 2, Pages (January 2010)

Presentation transcript:

Volume 65, Issue 5, Pages 1842-1849 (May 2004) Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo- controlled randomized study Bart D. Maes, Raymond Oyen, Kathleen Claes, Pieter Evenepoel, Dirk Kuypers, Johan Vanwalleghem, Boudewijn Van Damme, Yves F. Ch Vanrenterghem Kidney International Volume 65, Issue 5, Pages 1842-1849 (May 2004) DOI: 10.1111/j.1523-1755.2004.00588.x Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 1 Cumulative percentage of patients with IgA nephropathy (IgAN) treated with mycophenolate (MMF) or placebo (PLA). (A) Patients whose inulin clearance decreased by 25% or more. (B) Patients who were free of death, development of end-stage renal disease (ESRD), or premature discontinuation of therapy. (C) Patients whose serum creatinine increased by 50% or more during the 3-year treatment period. Kidney International 2004 65, 1842-1849DOI: (10.1111/j.1523-1755.2004.00588.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 2 Inulin clearance (A) (mean ± SEM), serum creatinine (B) (mean ± SEM) and annualized rate of change in serum creatinine (C) in patients with IgA nephropathy (IgAN) treated with mycophenolate mofetil (MMF) or placebo (PLA). Kidney International 2004 65, 1842-1849DOI: (10.1111/j.1523-1755.2004.00588.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 3 Bipolar diameter (mean of left and right kidney) (A) and parenchymal thickness (mean of left and right upper pole, interpolar region and lower pole) (B) (mean ± SEM) in patients with IgA nephropathy (IgAN) treated with mycophenolate mofetil (MMF) or placebo (PLA). Kidney International 2004 65, 1842-1849DOI: (10.1111/j.1523-1755.2004.00588.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 4 Mycophenolic acid (MPA) predose level (mean ± SEM) in patients with IgA nephropathy (IgAN) treated with mycophenolate mofetil (MMF). Kidney International 2004 65, 1842-1849DOI: (10.1111/j.1523-1755.2004.00588.x) Copyright © 2004 International Society of Nephrology Terms and Conditions